Smart Simon Bot with Public Sentiment Analysis for Novel Covid-19 Tweets Stratification.

In present modern era, the outbreak of COVID-19 pandemic has created informational crisis. The public sentiments collected from different reflexions (hashtags, comments, tweets, posts of twitter) are measured accordingly, ensuring different policy decisions and messaging are incorporated. The implementation demonstrates intuition in to the advancement of fear sentiment eventually as COVID-19 approaches maximum levels in the world, by making use of detailed textual analysis with the help of required text data visualization. In addition, technical outline of machine learning stratification approaches are provided in the frame of text analytics, and comparing their efficiency in stratifying coronavirus tweets of different lengths. Using Naïve Bayes method, 91% accuracy is achieved for short tweets and using logistic regression classification method, 74% accuracy is achieved for short tweets.

Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.

BACKGROUND: To provide the polio eradication initiative with more immunogenic oral poliovirus vaccines (OPVs), we evaluated newly developed monovalent type 1 OPV (mOPV1) among infants in India. METHODS: Two double-blind randomized controlled clinical trials compared two mOPV1s (mOPV1 A and mOPV1 B) versus trivalent OPV (tOPV X) given at birth (trial I), or assessed two products of higher-potency mOPV1 (mOPV1 C and mOPV1 D) versus regular-potency mOPV1 (mOPV1 B) or tOPV Y given at birth and at 30 days (trial II). RESULTS: In trial I, 597 newborns were enrolled, 66 withdrawn or excluded, leaving 531 (88.9%) subjects for analysis. Seroconversion to poliovirus type 1 was 10.4% for mOPV1 A, 15.6% for mOPV1 B and 10.2% for tOPV X. In trial II, 718 newborns were enrolled, 135 withdrawn or excluded, leaving 583 (81.2%) subjects for analysis. Seroconversion to poliovirus type 1 following a birth dose was 15.1%, 19.7%, 18.0% and 10.6%, following the 30-day dose 87.1%, 89.2%, 84.4%, or 55.9%, and cumulative for both doses 90.4%, 90.3%, 89.5% and 61.9% for mOPV1s B, C, and D and tOPV Y, respectively. CONCLUSIONS: In both studies, seronconversion rates were unexpectedly low to poliovirus type 1 after mOPV1 or tOPV given at birth but high for all formulations of mOPV1 given at age 30 days. The cause for low immunogenicity of OPV at birth in India is not known.